Evidence map›Paper›PMID 38487970›Full record

ArticleJournal of biomedical materials research. Part A2024

Influence of ionizable lipid tail length on lipid nanoparticle delivery of mRNA of varying length.

Kaitlin Mrksich, Marshall S Padilla, Ryann A Joseph, Emily L Han, Dongyoon Kim, Rohan Palanki, Junchao Xu, Michael J Mitchell

Open access · hybridAbstract read
In one paragraph

Article in Journal of biomedical materials research. Part A, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
11.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Cationic mRNA Lipid Nanoparticles for Ex Vivo NanoCAR-T Cell Engineering.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Harnessing mRNA-lipid nanoparticles as innovative therapies for autoimmune diseases.Molecular therapy. Methods & clinical development · 2025
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Kaitlin MrksichDepartment of Bioengineering, School of Engineering and Applied Science, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Marshall S PadillaDepartment of Bioengineering, School of Engineering and Applied Science, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Ryann A JosephDepartment of Bioengineering, School of Engineering and Applied Science, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Emily L HanDepartment of Bioengineering, School of Engineering and Applied Science, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Dongyoon KimDepartment of Bioengineering, School of Engineering and Applied Science, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Rohan PalankiDepartment of Bioengineering, School of Engineering and Applied Science, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Junchao XuDepartment of Bioengineering, School of Engineering and Applied Science, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Michael J MitchellDepartment of Bioengineering, School of Engineering and Applied Science, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0002-3628-2244
University of Pennsylvania · USCalifornia Institute for Regenerative Medicine · USChildren's Hospital of Philadelphia · US

Funding

A data-driven drug delivery (4D) platform for probing and treating the chemoresistant bone marrow microenvironmentDP2TR002776 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI MITCHELL, MICHAEL J · 2018 to 2018
$2.4M
Advanced Training at the Interface of Engineering and Oral-Craniofacial SciencesT90DE030854 · NIDCR · UNIVERSITY OF PENNSYLVANIA · PI Hyun Koo, Kathleen J Stebe · 2021 to 2026
$1.4M
Ionizable Lipid Nanoparticles for Fetal Lung TargetingF30HL162465 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI PALANKI, ROHAN · 2022 to 2025
$178k
American Cancer Society RSG-22-122-01-ETBurroughs Wellcome Fund Career Award at the Scientific Interface (CASI)Center for Innovation & Precision Dentistry (CiPD) at the University of PennsylvaniaNational Institute of Dental & Craniofacial Research (NIDCR) of the NIH under Award Number T90DE030854National Science Foundation (NSF) Graduate Research Fellowship 1845298NCATS NIH HHS DP2 TR002776NHLBI NIH HHS F30 HL162465NIDCR NIH HHS T90 DE030854NIH HHS DP2 TR002776NIH NHLBI F30 fellowship F30HL162465-01A1NSF CAREER Award CBET-2145491NSF Major Research Instrumentation Program NSF CHE-1827457US National Institutes of Health (NIH) Director's New Innovator AwardVagelos Institute for Energy Science and Technology
6 · The paper itself

Abstract

RNA-based therapeutics have gained traction for the prevention and treatment of a variety of diseases. However, their fragility and immunogenicity necessitate a drug carrier. Lipid nanoparticles (LNPs) have emerged as the predominant delivery vehicle for RNA therapeutics. An important component of LNPs is the ionizable lipid (IL), which is protonated in the acidic environment of the endosome, prompting cargo release into the cytosol. Currently, there is growing evidence that the structure of IL lipid tails significantly impacts the efficacy of LNP-mediated mRNA translation. Here, we optimized IL tail length for LNP-mediated delivery of three different mRNA cargos. Using C12-200, a gold standard IL, as a model, we designed a library of ILs with varying tail lengths and evaluated their potency in vivo. We demonstrated that small changes in lipophilicity can drastically increase or decrease mRNA translation. We identified that LNPs formulated with firefly luciferase mRNA (1929 base pairs) and C10-200, an IL with shorter tail lengths than C12-200, enhance liver transfection by over 10-fold. Furthermore, different IL tail lengths were found to be ideal for transfection of LNPs encapsulating mRNA cargos of varying sizes. LNPs formulated with erythropoietin (EPO), responsible for stimulating red blood cell production, mRNA (858 base pairs), and the C13-200 IL led to EPO translation at levels similar to the C12-200 LNP. The LNPs formulated with Cas9 mRNA (4521 base pairs) and the C9-200 IL induced over three times the quantity of indels compared with the C12-200 LNP. Our findings suggest that shorter IL tails may lead to higher transfection of LNPs encapsulating larger mRNAs, and that longer IL tails may be more efficacious for delivering smaller mRNA cargos. We envision that the results of this project can be utilized as future design criteria for the next generation of LNP delivery systems for RNA therapeutics.

Indexed as

LipidsNanoparticlesRNA, MessengerAnimalsHumansLiposomesMiceTransfectionLipid NanoparticlesLipidsLiposomesRNA, MessengerIonizable lipidlipid nanoparticlemRNA

Identifiers

PMID38487970
PMCPMC11239295
OpenAlexW4392851800

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.